Lambert-Eaton Myasthenic Syndrome Market By Treatment (Potassium Channel Blockers (Amifampridine), Cholinesterase Inhibitor (Pyridostigmine), Immune Therapy, Intravenous Immunoglobulin, Plasmapheresis) - Growth, Future Prospects And Competitive Landscape, 2019 – 2027

The Lambert-Eaton myasthenic syndrome (LEMS) market is keen to represent linear growth at a compounded annual growth rate (CAGR) of 6.7% during the forecast period from 2019 to 2027. LEMS is a rare autoimmune disorder that is manifested by the clinical triad of reduced tendon reflexes, autonomic symptoms, and proximal muscle weakness. Because of the overlapping symptoms with small cell lung cancer (SCLC), the majority of LEMS patients go undiagnosed at a young age.

Market Synopsis

Recent FDA approval of amifampridine for the treatment of LEMS in children, as well as fast track and orphan drug designation, will encourage growth during the forecast period.

Currently, there is no permanent cure for the treatment of LEMS disease in children; the medicine prescribed by physicians worldwide is intended to attenuate the clinical manifestations related to LEMS disease. Depending on the identification of the symptoms occurring in the adult population, the drugs prescribed for their treatment are potassium channel blockers, cholinesterase inhibitors, immune therapy, intravenous immunoglobulin, plasmapheresis, etc.

The USFDA has recently approved amifampridine for the treatment of LEMS in children from 6 to 17 years of age. It has received orphan drug and fast-track designation status, which will proactively incentivize drug development for curing rare diseases.

A significant rise in clinical research to cure orphan diseases and the domicile of major players together drive the market's growth in the North American region.

North America is currently dominating the regional segment of the Lambert-Eaton myasthenic syndrome (LEMS) market, holding 39% of the market. The significant increase in clinical research activities to cure orphan diseases is one of the major factors responsible for its positive growth profile.

According to the Centers for Disease Control and Prevention (CDC), research findings indicate that approximately 3% of the patients suffering from small cell lung cancer (SCLC) suffer from Lambert-Eaton myasthenic syndrome (LEMS). The prevalence rate of SCLC in the United States is 5 cases per million people.

The dominance of major players such as Biomarin Pharmaceutical, Inc., Catalyst Pharmaceuticals, Inc., Merck & Co., Inc., etc., propels market growth in the North American region. Europe holds the second position, representing a market share of 34.5%, owing to the high incidence rate of LEMS in the European community. As per the research cited by the European LEMS Registry, the incidence rate is 0.48 to 0.75 per million people.

The low prevalence rate in comparison to the incidence rate is due to the poor survival of LEMS patients with paraneoplastic types of disease. Asia Pacific is currently holding 14% of the market, primarily due to the large patient population suffering from SCLC and proactive government initiatives in providing financial aid for the treatment of rare diseases.

Periods of History and Forecast

This research report presents the analysis of each segment from 2017 to 2027,considering 2018as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

The market is segmented by treatment and by geography.

Pharmaceutical manufacturers providing medications for the treatment of Lambert-Eaton myasthenic syndrome are Allergan, Plc., Biomarin Pharmaceutical, Inc., Catalyst Pharmaceuticals, Inc., F. Hoffman-La Roche Ltd., GlaxoSmithKline, Plc., Jacobus Pharmaceutical Company, Inc., Kawasumi Laboratories, Inc., Merck & Co., Inc., and Mitsubishi Pharma Corporation.

Key questions are answered in this report.

  • Which pharmaceutical companies are engaged in the treatment of LEMS?
  • What is the global prevalence rate of LEMS and its clinical manifestations that overlap with cancer?
  • A brief explanation of DROs associated with the LEMS market?
  • Which drug received the USFDA orphan drug designation and fast-track designation for the treatment of LEMS in children?
  • What is the incidence rate in developed countries such as Europe and North America?

Frequently Asked Question:

The market for Lambert-Eaton Myasthenic Syndrome Market is expected to reach USD$ XX in 2027.

The Lambert-Eaton Myasthenic Syndrome Market is expected to see significant CAGR growth over the coming years, at 6.7%.

The report is forecasted from 2019 -2027.

The base year of this report is 2018.

Biomarin Pharmaceutical, Inc., Catalyst Pharmaceuticals, Inc., Merck & Co., Inc. are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Jun 2019
Category:  Pharmaceuticals
Report ID:   59722
Report Format:   PDF
Pages:   120
Rating:    4.4 (56)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support